FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315490878> ?p ?o ?g. }

• W4315490878 abstract "Abstract Introduction/Aims: Muscle cramps are a common and often disabling symptom in Amyotrophic Lateral Sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in this patient population may sustain quality of life longer. A traditional Japanese medicine, shakuyakukanzoto (TJ-68) is widely prescribed in Japan for managing muscle cramps in a variety of conditions. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, this clinical trial is designed to test the safety and efficacy of TJ-68 in participants with ALS reporting serious muscle cramps using a personalized N-of-1 approach. If successful, we can introduce TJ-68 for muscle cramps in ALS to Western medicine. Methods: With FDA-IND approval, we are conducting a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study was sized to detect a one-point shift on the Columbia Muscle Cramp Scale (MCS) item #5 with 85% power under a four-period crossover design.The secondary assessment includes the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). Discussion: The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate MCS in rare disorders. If TJ-68 proves safe and efficacious, we will work to introduce this product to Western medicine for treatment of patients with ALS and disabling muscle cramps. Trial Registration: This clinical trial has been registered with ClinicalTrials.gov (NCT04998305)." @default.
• W4315490878 created "2023-01-11" @default.
• W4315490878 creator A5007820802 @default.
• W4315490878 creator A5016627090 @default.
• W4315490878 creator A5024884035 @default.
• W4315490878 creator A5032726191 @default.
• W4315490878 creator A5042856673 @default.
• W4315490878 creator A5052581382 @default.
• W4315490878 creator A5063229609 @default.
• W4315490878 creator A5068006343 @default.
• W4315490878 creator A5070593246 @default.
• W4315490878 creator A5084377118 @default.
• W4315490878 date "2023-01-10" @default.
• W4315490878 modified "2023-10-14" @default.
• W4315490878 title "Randomized Double-Blind Personalized N-of-1 Clinical Trial to Test the Safety and Potential Efficacy of TJ-68 for Treating Muscle Cramps in Amyotrophic Lateral Sclerosis (ALS): study protocol for a TJ-68 trial." @default.
• W4315490878 cites W1605803992 @default.
• W4315490878 cites W1891787316 @default.
• W4315490878 cites W1967247321 @default.
• W4315490878 cites W1984289632 @default.
• W4315490878 cites W1993142542 @default.
• W4315490878 cites W1996649698 @default.
• W4315490878 cites W2007909816 @default.
• W4315490878 cites W2026287816 @default.
• W4315490878 cites W2042543920 @default.
• W4315490878 cites W2050626075 @default.
• W4315490878 cites W2065277090 @default.
• W4315490878 cites W2085165928 @default.
• W4315490878 cites W2089034809 @default.
• W4315490878 cites W2097250361 @default.
• W4315490878 cites W2104210715 @default.
• W4315490878 cites W2107237825 @default.
• W4315490878 cites W2110293983 @default.
• W4315490878 cites W2128328728 @default.
• W4315490878 cites W2157194959 @default.
• W4315490878 cites W2161938104 @default.
• W4315490878 cites W2165729154 @default.
• W4315490878 cites W2566453217 @default.
• W4315490878 cites W2616124858 @default.
• W4315490878 cites W2795678885 @default.
• W4315490878 cites W2889165458 @default.
• W4315490878 cites W2941202801 @default.
• W4315490878 cites W2979520562 @default.
• W4315490878 cites W3015372504 @default.
• W4315490878 cites W3082122716 @default.
• W4315490878 cites W3092893535 @default.
• W4315490878 cites W4229000223 @default.
• W4315490878 cites W4289840034 @default.
• W4315490878 cites W4295866179 @default.
• W4315490878 doi "https://doi.org/10.21203/rs.3.rs-2402049/v1" @default.
• W4315490878 hasPublicationYear "2023" @default.
• W4315490878 type Work @default.
• W4315490878 citedByCount "0" @default.
• W4315490878 crossrefType "posted-content" @default.
• W4315490878 hasAuthorship W4315490878A5007820802 @default.
• W4315490878 hasAuthorship W4315490878A5016627090 @default.
• W4315490878 hasAuthorship W4315490878A5024884035 @default.
• W4315490878 hasAuthorship W4315490878A5032726191 @default.
• W4315490878 hasAuthorship W4315490878A5042856673 @default.
• W4315490878 hasAuthorship W4315490878A5052581382 @default.
• W4315490878 hasAuthorship W4315490878A5063229609 @default.
• W4315490878 hasAuthorship W4315490878A5068006343 @default.
• W4315490878 hasAuthorship W4315490878A5070593246 @default.
• W4315490878 hasAuthorship W4315490878A5084377118 @default.
• W4315490878 hasBestOaLocation W43154908781 @default.
• W4315490878 hasConcept C126322002 @default.
• W4315490878 hasConcept C142724271 @default.
• W4315490878 hasConcept C159110408 @default.
• W4315490878 hasConcept C168563851 @default.
• W4315490878 hasConcept C1862650 @default.
• W4315490878 hasConcept C204787440 @default.
• W4315490878 hasConcept C27081682 @default.
• W4315490878 hasConcept C2779134260 @default.
• W4315490878 hasConcept C2779819292 @default.
• W4315490878 hasConcept C2779951463 @default.
• W4315490878 hasConcept C2780596555 @default.
• W4315490878 hasConcept C2908647359 @default.
• W4315490878 hasConcept C535046627 @default.
• W4315490878 hasConcept C71924100 @default.
• W4315490878 hasConcept C87813604 @default.
• W4315490878 hasConcept C99454951 @default.
• W4315490878 hasConcept C99508421 @default.
• W4315490878 hasConceptScore W4315490878C126322002 @default.
• W4315490878 hasConceptScore W4315490878C142724271 @default.
• W4315490878 hasConceptScore W4315490878C159110408 @default.
• W4315490878 hasConceptScore W4315490878C168563851 @default.
• W4315490878 hasConceptScore W4315490878C1862650 @default.
• W4315490878 hasConceptScore W4315490878C204787440 @default.
• W4315490878 hasConceptScore W4315490878C27081682 @default.
• W4315490878 hasConceptScore W4315490878C2779134260 @default.
• W4315490878 hasConceptScore W4315490878C2779819292 @default.
• W4315490878 hasConceptScore W4315490878C2779951463 @default.
• W4315490878 hasConceptScore W4315490878C2780596555 @default.
• W4315490878 hasConceptScore W4315490878C2908647359 @default.
• W4315490878 hasConceptScore W4315490878C535046627 @default.
• W4315490878 hasConceptScore W4315490878C71924100 @default.
• W4315490878 hasConceptScore W4315490878C87813604 @default.
• W4315490878 hasConceptScore W4315490878C99454951 @default.
• W4315490878 hasConceptScore W4315490878C99508421 @default.
• W4315490878 hasLocation W43154908781 @default.
• W4315490878 hasOpenAccess W4315490878 @default.

• next